Global Information
회사소개 | 문의 | 비교리스트

교아종(GBM) : Market Spotlight

Market Spotlight: Glioblastoma (GBM)

리서치사 Datamonitor Healthcare
발행일 2021년 05월 상품코드 1019950
페이지 정보 영문 54 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 1,318 ₩ 1,872,000 PDF (Single User License)


교아종(GBM) : Market Spotlight Market Spotlight: Glioblastoma (GBM)
발행일 : 2021년 05월 페이지 정보 : 영문 54 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계에서 교아종의 이환 수는 2019년에 7만 7,000건으로 추산되고 있으며, 2028년에는 9만 1,800건으로 증가할 것으로 예측됩니다. 2019년에 진단된 증례의 대부분은 남성으로 추산되고 있습니다. 교아종영역의 승인약은 DNA, 혈관내피세포성장인자, DNA 합성, 단백질 합성, RNA 합성에 초점을 맞추고 있습니다. 이 약제는 교아종에 대해 정맥내 투여, 종양내 투여, 경구투여의 각 루트로 투여됩니다.

교아종(GBM)에 대해 조사했으며, 질환 배경, 치료, 역학, 의약품 및 파이프라인약, 임상시험 상황, 매출 기회 등의 정보를 정리하여 전해드립니다.

목차

컨텐츠

개요

요점

질병 배경

  • 질병의 정의
  • 환자 세분화
  • 증상
  • 위험 요인
  • 진단

치료

  • 수술
  • 방사선 치료
  • 화학요법
  • 종양 치료 필드(TTF)
  • 표적치료

역학

의약품

파이프라인약

최근 이벤트와 애널리스트의 의견

  • 교아종용 DNX-2401(2020년 11월 20일)
  • 교아종용 Omburtamab(2020년 10월 16일)
  • 교아종용 AG-881(2020년 5월 29일)
  • 교아종용 FT-2102(2020년 5월 28일)

향후 주요 이벤트

주요 규제 이벤트

  • Innovent의 아달리무맙과 베바시주맙이 중국에서 새로운 적응을 획득
  • 중국이 국민 회의를 향해 준비를 진행시키는 가운데 각광을 받는 새로운 승인

성공 확률

라이선싱 및 자산 취득 거래

  • Lineage, 뇌종양 면역치료의 면역 파트너
  • UroGen, Johns Hopkins가 뇌종양 면역치료를 연구
  • Simcere가 중국 플러스 에어리어에서 Kazia의 Paxalisib를 픽업
  • Chimerix는 Oncoceutics를 7,800만 달러에 인수
  • Agios는 암 포트폴리오를 Servier에 매각하고, 유전성 질환에 주력
  • Connectyx는 뇌종양에 대한 NCI 항체의 사용을 검토
  • Telix가 중화권에서의 얼라이언스에 China Grand를 선택
  • CityofHope가 CTLX-CAR-T 후보를 Chimeric에 라이선싱
  • Cytovia가 CytoImmune의 CAR 후보에 대한 권리를 취득

매출 기회

임상시험 상황

  • 현황별 스폰서
  • 단계별 스폰서
  • 최근 이벤트

참고 문헌

부록

도표 리스트

표 리스트

KSA 21.08.19

This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 77,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 91,800 incident cases by 2028.

It is estimated that the majority of diagnosed cases were in males in 2019. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intratumoral, and oral routes for glioblastoma.

The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with only one drug in the NDA/BLA phase.

Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I trial results, topline Phase I/II trial results, topline Phase II trial results, topline Phase III trial results, Phase III updated trial results, and an expected PDUFA date.

The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.

The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 80 trials.

Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, closely followed by Roche.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Tumor-treating fields (TTFs)
  • Targeted therapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • DNX-2401 for Glioblastoma (November 20, 2020)
  • Omburtamab for Glioblastoma (October 16, 2020)
  • AG-881 for Glioblastoma (May 29, 2020)
  • FT-2102 for Glioblastoma (May 28, 2020)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Innovent's Adalimumab And Bevacizumab Get New Indications In China
  • New Approvals In Spotlight As China Gears For National Congress

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Lineage, Immunomic Partner On Brain Cancer Immunotherapy
  • UroGen, Johns Hopkins Investigate Brain Cancer Immunotherapy
  • Simcere Picks Up Kazia's Paxalisib In China-Plus Area
  • Chimerix Pays $78m To Acquire Oncoceutics
  • Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
  • Connectyx Explores Use Of NCI Antibody For Brain Cancer
  • Telix Chooses China Grand In Greater China Alliance
  • City of Hope Licenses CTLX-CAR-T Candidate To Chimeric
  • Cytovia Obtains Rights To CytoImmune's CAR Candidate

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent Events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of glioblastoma, 2019-28
  • Figure 2: Overview of pipeline drugs for glioblastoma in the US
  • Figure 3: Pipeline drugs for glioblastoma, by company
  • Figure 4: Pipeline drugs for glioblastoma, by drug type
  • Figure 5: Pipeline drugs for glioblastoma, by classification
  • Figure 6: DNX-2401 for Glioblastoma (November 20, 2020): Phase II - CAPTIVE/KEYNOTE-192 - w/Keytruda
  • Figure 7: Omburtamab for Glioblastoma (October 16, 2020): Phase II/III - 101 (Neuroblastoma Central Nervous System/Leptomeningeal Metastases)
  • Figure 8: FT-2102 for Glioblastoma (May 28, 2020): Phase I/II - 2101-ONC-102
  • Figure 9: Key upcoming events in glioblastoma
  • Figure 10: Probability of success in the solid tumors pipeline
  • Figure 11: Clinical trials in glioblastoma
  • Figure 12: Top 10 drugs for clinical trials in glioblastoma
  • Figure 13: Top 10 companies for clinical trials in glioblastoma
  • Figure 14: Trial locations in glioblastoma
  • Figure 15: Glioblastoma trials status
  • Figure 16: Glioblastoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Global incident cases of glioblastoma, 2019-28
  • Table 2: Incident cases of glioblastoma, by gender, 2019
  • Table 3: Marketed drugs for glioblastoma
  • Table 4: Pipeline drugs for glioblastoma in the US
  • Table 5: DNX-2401 for Glioblastoma (November 20, 2020)
  • Table 6: Omburtamab for Glioblastoma (October 16, 2020)
  • Table 7: AG-881 for Glioblastoma (May 29, 2020)
  • Table 8: FT-2102 for Glioblastoma (May 28, 2020)
  • Table 9: Historical global sales, by drug ($m), 2016-20
  • Table 10: Forecasted global sales, by drug ($m), 2021-25
Back to Top
전화 문의
F A Q